MALVERN, Pa., July 8, 2019 /PRNewswire/ -- Neuronetics, Inc. (NASDAQ: STIM) – Neuronetics, Inc., the developer of NeuroStar® Advanced Therapy, announced today that its depression outcomes registry has reached 3,223 evaluable patients, making it the largest outcomes registry in the world for Major Depressive Disorder (MDD). Launched in

CAMBRIDGE, Mass., July 8, 2019 /PRNewswire/ -- A new study published in the inaugural issue of the

Skyhawk will deploy its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases and cancer.  In exchange, Skyhawk is eligible to receive approximately $600 million per program target consisting of an upfront cash payment and, if Merck exercises its option, potential opt-in fees, milestone payments, as well as royalties on s

- Skyhawk to expand its collaboration with Biogen to develop novel small molecule RNA splicing modifiers for disease targets- Biogen to pay Skyhawk additional upfront and potential future milestone payments and royalties WALTHAM, Mass., July 8, 2019 /PRNewswire/ -- Skyhawk Therapeutics, Inc. ("Skyhawk") today announced the expansion of its collaborati

NEW YORK and CAESAREA, Israel, July 8, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO) today announced that on

STOCKHOLM, July 8, 2019 /PRNewswire/ -- On 17 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the seco

VAUGHAN, ON, July 8, 2019 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) has received a compliance report from Health Canada notifying the Company that its greenhouse facility in Pelham, Ontario is non-compliant with certain regulations. CannTrust has accepted Health Canada's non-compliance fi

- Tyler Jacks, Ph.D., head of the Koch Institute for Integrative Cancer Research at MIT, joins as Chair of Skyhawk's Scientific Advisory Board- Tai Wong, Ph.D., former Vice President Biology of Peloton Therapeutics, now being acquired by Merck, joins Skyhawk as Vice President, Oncology Biology

PRINCETON, N.J., July 8, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Ms. Diane L. Parks

CAMBRIDGE, Mass., July 8, 2019 /PRNewswire/ -- EIP Pharma, Inc. a CNS-focused therapeutics company, today announced that it has expanded its leadership team with the appointment of Noel Donnelly as CFO. Mr. Donnelly joins EIP Pharma from Takeda Pharmaceuticals where he led a group focused on strategy and operations.